Divalproex Sodium

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

67 API Suppliers, 36 USDMF, 10 CEP/COS, 3 JDMF, 8 EU WC, 9 KDMF, 15 NDC API, 34 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

266 FDF Dossiers, 109 FDA Orange Book, 57 Europe, 17 Canada, 30 Australia, 17 South Africa, 36 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SYRUP;ORAL - 250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 125MG VALPROIC ACID, TABLET, DELAYED RELEASE;ORAL - EQ 250MG VALPROIC ACID, TABLET, DELAYED RELEASE;ORAL - EQ 500MG VALPROIC ACID, CAPSULE, DELAYED REL PELLETS;ORAL - EQ 125MG VALPROIC ACID, TABLET, EXTENDED RELEASE;ORAL - EQ 250MG VALPROIC ACID, TABLET, EXTENDED RELEASE;ORAL - EQ 500MG VALPROIC ACID

RELATED EXCIPIENT COMPANIES

3 Evonik, 3 Rochem International Inc, 19 SPI Pharma, 2 Seqens, 14 DKSH, 1 Pharm-RX Chemical, 8 Faran Shimi Pharmaceutical, 11 Boai NKY Pharmaceuticals Ltd, 13 Gangwal Healthcare, 9 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 3 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 38 BASF, 2 Clariant, 18 Corel Pharma Chem, 6 DFE Pharma, 3 Doshion Polyscience, 2 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 16 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 34 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 18 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 5 Novo Excipients, 4 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 27 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 3 The Dow Chemical Company, 2 Ulanqab Kema New Material, 3 Valens Pharmachem, 4 Vasa Pharmachem, 2 Vertellus

EXCIPIENTS BY APPLICATIONS

108 Fillers, Diluents & Binders, 84 Coating Systems & Additives, 52 Direct Compression, 51 Controlled & Modified Release, 43 Disintegrants & Superdisintegrants, 42 Thickeners and Stabilizers, 39 Solubilizers, 35 Granulation, 33 Taste Masking, 28 Film Formers & Plasticizers, 26 Topical, 23 Parenteral, 23 Lubricants & Glidants, 21 Co-Processed Excipients, 18 Chewable & Orodispersible Aids, 11 Emulsifying Agents, 10 Rheology Modifiers, 10 API Stability Enhancers, 9 Empty Capsules, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 60 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 91 Finished Drug Prices, 5 Annual Reports

MARKET PLACE

25 APIs, 16 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 3 USP, 4 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 18082 / DOSAGE - SYRUP;ORAL - 250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
VALPROIC ACID(UNII: 614OI1Z5WI) (VALPROIC ACID - UNII:614OI1Z5WI)	VALPROIC ACID	250mg \| 250mg in 5

Inactive Ingredients

Ingredient Name	AbbVie Inc.
CORN OIL(8470G57WFM)
FD&C RED NO. 40(WZB9127XOA)
FD&C YELLOW NO. 6(H77VEI93A8)
FERRIC OXIDE RED(1K09F3G675)
GELATIN, UNSPECIFIED(2G86QN327L)
GLYCERIN(PDC6A3C0OX)
METHYLPARABEN(A2I8C7HI9T)
PROPYLPARABEN(Z8IX2SC1OH)
SORBITOL(506T60A25R)
SUCROSE(C151H8M554)
TITANIUM DIOXIDE(15FIX9V2JP)
VANILLIN(CHI530446X)
WATER(059QF0KO0R)

Drug Product Composition: Divalproex Sodium